Creative Medical Technology - CELZ Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.31
+0 (0.00%)

This chart shows the closing price for CELZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Creative Medical Technology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELZ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Creative Medical Technology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.31.

This chart shows the closing price for CELZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Creative Medical Technology. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/24/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/25/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/24/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/23/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/20/2026Roth CapitalReiterated RatingBuy ➝ Buy
8/13/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
7/31/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
5/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/11/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/12/2025Zacks ResearchUpgradeHold
2/25/2022Roth CapitalInitiated CoverageBuy$100.00
(Data available from 8/24/2021 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2026
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2026
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2026

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Creative Medical Technology logo
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Read More

Today's Range

Now: $1.31
Low: $1.22
High: $1.35

50 Day Range

MA: $1.20
Low: $0.65
High: $2.39

52 Week Range

Now: $1.31
Low: $0.62
High: $6.25

Volume

544,953 shs

Average Volume

20,170,044 shs

Market Capitalization

$8.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Creative Medical Technology?

The following Wall Street analysts have issued stock ratings on Creative Medical Technology in the last year: Roth Capital, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for CELZ.

What is the current price target for Creative Medical Technology?

0 Wall Street analysts have set twelve-month price targets for Creative Medical Technology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Creative Medical Technology in the next year.
View the latest price targets for CELZ.

What is the current consensus analyst rating for Creative Medical Technology?

Creative Medical Technology currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CELZ, but not buy more shares or sell existing shares.
View the latest ratings for CELZ.

What other companies compete with Creative Medical Technology?

How do I contact Creative Medical Technology's investor relations team?

Creative Medical Technology's physical mailing address is 2017 W Peoria Ave, PHOENIX, AZ 85029-4916, United States. The company's listed phone number is (833) 336-7636 and its investor relations email address is [email protected]. The official website for Creative Medical Technology is www.creativemedicaltechnology.com. Learn More about contacing Creative Medical Technology investor relations.